Skip to main content
Clinical Trials/NCT06502509
NCT06502509CompletedNot Applicable

How Does Kombucha Tea Improve Difficulty During Defecation in Patients With Schizophrenia- A Randomized, Double-blinded, Placebo-controlled, Parallel Study

TsaoTun Psychiatric Center, Department of Health, Taiwan2 sites in 1 country80 target enrollmentStarted: March 11, 2024Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
80
Locations
2
Primary Endpoint
The objective amelioration of stool passage

Study Overview

Brief Summary

Patients with schizophrenia frequently have difficulties in bowel habits due to medical adverse effects and unhealthy lifestyle, and the use of various interventions to ameliorate the problems have been noted in clinical setting. Probiotics including Kombucha tea have been proved to modulate the human gut microbiota which may help to improve the stool passage, and have been attracting the public attention across the world. However, little is known among the patients with schizophrenia. In the present study, the research team intends to evaluate effectiveness of Kombucha tea when used in the clinical settings.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Supportive Care
Masking
Double (Participant, Outcomes Assessor)

Eligibility Criteria

Ages
20 Years to 65 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Inclusion Criteria:
  • Inpatient patients diagnosed of schizophrenia according to DSM-5 criteria with the ICD-10-CM codes of F20.x. and hold the cards for Severe Illness issued by the National Health Insurance Administration, and
  • Are currently and have been hospitalized at the psychiatric rehabilitation ward for more than 6 months, and
  • Are at relatively stable psychiatric state and able to clearly express their perception or observed bowel conditions, and
  • Are able to read or communicate with Mandarin or Taiwanese, and
  • Are able to consent the agreements, and
  • Subjectively experience difficulty in stool passage, such as decreased frequency, requiring medication or mechanic aids for defecating.

Exclusion Criteria

  • 1. Having an allergic history to fermented food, alcohol or other food, or
  • Severely impaired in cognitive performance, or
  • Having medications, antibiotics, probiotic or other fermented products that may influence gut microbiota at the time or within 3 months of the study, or
  • Having the illness that may affect stool passage or related with intestinal obstruction, such as severe gut disease, intestinal incarceration, tumor, inflammation, stenosis, or hemorrhoid, or
  • Having received major gastro-intestinal surgeries, or
  • Having the ongoing or history of medical illnesses, such as cancers, chronic obstructive pulmonary diseases, peripheral vascular diseases, autoimmune diseases, chronic kidney diseases, diseases involving abnormal metabolic function of visceral organs, or current infections, or
  • Participating other ongoing interventional research that may interfere the implementation or the results of present studies, or
  • Being obviously unable to comply with the execution of the study, or
  • Being declared of guardianship.

Outcomes

Primary Outcomes

The objective amelioration of stool passage

Time Frame: The objective outcome will be assessed at baseline, week 4, 8 and 12 (endpoint).

The objective amelioration of stool passage: the frequency or the amount of laxative agent use recorded in clinical care.

The subjective amelioration of stool passage

Time Frame: The subjective main outcome will be assessed weekly for 12 weeks.

The subjective amelioration of stool passage: the participants' perceived overall ease of feces on a VAS scale.

Secondary Outcomes

  • Adverse effects Adverse effects Adverse effects Adverse effects(Adverse effects will be assessed weekly from Week 1 to Week 12.)
  • Stool form(Stool form will be assessed daily from Week 1 to Week 12.)
  • The participants' perceived flatulence, ease and frequency of stool passage.(The participants' perceived flatulence, ease and frequency of stool passage will be assessed weekly from Week 1 to Week 12.)

Investigators

Sponsor
TsaoTun Psychiatric Center, Department of Health, Taiwan
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

An-Yu Hong

Doctor

TsaoTun Psychiatric Center, Department of Health, Taiwan

Study Sites (2)

Loading locations...

Similar Trials